All News
Presenting Features of Early SLE
What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics? A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.
Read ArticleArtificial Intelligence to Predict Rheumatoid Disease Activity
A recent study in JAMA Network Open shows that artificial intelligence models can use electronic health record data to prognosticate future patient outcomes in rheumatoid arthritis (RA).
Read ArticleImproved Mortality Trends in Lupus Nephritis
The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.
Read ArticleRisky Painkillers Commonly Prescribed for Osteoarthritis
Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling.
Read ArticleIronwood Retreats from the US Gout Market
Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.
Read ArticleNo Rise in Cancer Risk with Actemra
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
Read ArticleCRA Position Statement on Medical Cannabis Use
Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.
Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.
Read ArticleRheumNow Podcast – You Owe Me a DEXA (3.15.19)
Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.
Read ArticleLower TNF Inhibitor Persistence in Spondylitis
A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.
Read ArticleFirst Line IL-1 Inhibition in Systemic JIA
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.
Read ArticleEULAR Consensus Guidelines for Juvenile Localized Scleroderma
A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).
Read Article2018 Swedish Guidelines for Giant Cell Arteritis Treatment
The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab.
Read ArticleMultiple Delays in Referral of New RA Patients
A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.
Read ArticleLower Mortality Results from Lower Activity in Lupus
Data from the longitudinal Tromsø Lupus Cohort study has shown that lupus patients who achieve a Lupus Low Disease Activity State (LLDAS‐50) were shown to have significantly less severe damage, and a reduction in mortality.
This was a population‐based study of SLE patients in the northern‐most counties of Norway.
Dual IL-17 Inhibitor in Psoriasis Succeeds
Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.
Read ArticleMedical Meetings: Should I Stay or Should I Go?
Say a conference in your field was just announced. You think you "should" go, and you know you'll be choosing from many presentation opportunities that feature the latest research — which you want to know about. And you'll get to hang with like minds and talk about things that matter.
Read ArticleAAD/NPF Guidelines on Biologic Use in Psoriasis
Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.
Read ArticleEarly TNF inhibition in Early Psoriatic Arthritis
A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.
Read ArticleSenate Drills Drug Makers Over Price
Reuters reported that today, the US Senate Finance Committee met to question the executives from seven US pharmaceutical companies on the rising price drugs in America.
Read ArticleCanadian Vaccination Guidelines for the Immunosuppressed
A multidisciplinary Canadian task force has developed guidelines for vaccination in patients receiving immunosuppressive therapies, based on the evidence that immunosuppressive use in immune-mediated disease may be associated with an elevated risk of infections.
Read Article